Full Text of HB4243 103rd General Assembly
HB4243 103RD GENERAL ASSEMBLY | | | 103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024 HB4243 Introduced 1/16/2024, by Rep. Jed Davis SYNOPSIS AS INTRODUCED: | | 210 ILCS 25/7-108 | from Ch. 111 1/2, par. 627-108 | 210 ILCS 25/7-110 | from Ch. 111 1/2, par. 627-110 | 210 ILCS 25/7-111 | from Ch. 111 1/2, par. 627-111 | 210 ILCS 25/7-120 new | |
| Amends the Illinois Clinical Laboratory and Blood Bank Act. Requires a blood bank to test or have tested donated blood for evidence of any COVID-19 vaccine and any other messenger ribonucleic acid (mRNA) vaccine components, and requires a blood donor to disclose during each blood donor screening process whether the blood donor has received a COVID-19 vaccine or any other mRNA vaccine during the donor's lifetime. Requires blood or blood components to include on their labels a designation that the blood or blood components tested positive for evidence of a COVID-19 vaccine or any other mRNA vaccine component or was drawn from a blood donor who disclosed the donor have received a COVID-19 vaccine or any other mRNA vaccine during the donor's lifetime. Provides that the Department of Public Health must adopt rules to implement the changes made by the amendatory Act. |
| |
| | A BILL FOR |
| | | | HB4243 | | LRB103 34691 AWJ 64536 b |
|
| 1 | | AN ACT concerning regulation. | 2 | | Be it enacted by the People of the State of Illinois, | 3 | | represented in the General Assembly: | 4 | | Section 5. The Illinois Clinical Laboratory and Blood Bank | 5 | | Act is amended by changing Sections 7-108, 7-110, and 7-111 | 6 | | and by adding Section 7-120 as follows: | 7 | | (210 ILCS 25/7-108) (from Ch. 111 1/2, par. 627-108) | 8 | | Sec. 7-108. Duties of blood banks. A blood bank shall: | 9 | | (a) Collect, process, and provide for use blood or blood | 10 | | components from a blood donor only upon the consent of that | 11 | | donor and under the direction or delegated direction of the | 12 | | blood bank Medical Director. | 13 | | (b) Transfuse blood or blood components upon the request | 14 | | of a physician licensed to practice medicine in all its | 15 | | branches, a dentist, or a podiatric physician who is on the | 16 | | medical staff of a hospital and has permission from the | 17 | | medical staff to make such a request. If the request is oral, | 18 | | the physician or other authorized person shall submit a | 19 | | written request to the blood bank within 48 hours. If the blood | 20 | | bank does not receive the written request within that period, | 21 | | it shall note that fact in its records. | 22 | | (c) Test or have tested donated blood for evidence of any | 23 | | COVID-19 vaccine or any other messenger ribonucleic acid |
| | | HB4243 | - 2 - | LRB103 34691 AWJ 64536 b |
|
| 1 | | (mRNA) vaccine components, including evidence of lipid | 2 | | nanoparticles and spike protein from a vaccine. | 3 | | (d) Require a blood donor to disclose, during each blood | 4 | | donor screening process, whether the blood donor has received | 5 | | a COVID-19 vaccine or any other mRNA vaccine during the | 6 | | donor's lifetime. | 7 | | (Source: P.A. 98-214, eff. 8-9-13.) | 8 | | (210 ILCS 25/7-110) (from Ch. 111 1/2, par. 627-110) | 9 | | Sec. 7-110. Blood labeling. Every person who withdraws | 10 | | blood from an individual or separates blood into components by | 11 | | physical processes shall affix to each container of blood or | 12 | | blood components a label that includes (1) the appropriate | 13 | | donor classification, "volunteer donor" or "paid donor", in no | 14 | | less prominence than the word "blood" or the name of the blood | 15 | | component and (2) a designation, if true, that the blood | 16 | | tested positive for evidence of a COVID-19 vaccine or any | 17 | | other messenger ribonucleic acid (mRNA) vaccine or was drawn | 18 | | from a blood donor who disclosed that the donor has received a | 19 | | COVID-19 vaccine or any other mRNA vaccine during the donor's | 20 | | lifetime . | 21 | | Any person who receives blood or blood components in this | 22 | | State from a federally licensed blood bank in another state | 23 | | shall not be required to relabel a container of blood or blood | 24 | | components if the container of blood or blood components is | 25 | | labeled with the appropriate donor classification, "volunteer |
| | | HB4243 | - 3 - | LRB103 34691 AWJ 64536 b |
|
| 1 | | donor" or "paid donor", in no less prominence than the word | 2 | | "blood" or the name of the blood component. | 3 | | (Source: P.A. 87-1269.) | 4 | | (210 ILCS 25/7-111) (from Ch. 111 1/2, par. 627-111) | 5 | | Sec. 7-111. Administration of labeled blood. No person may | 6 | | administer blood by transfusion in this State or transfer or | 7 | | offer to transfer blood for transfusion purposes by any type | 8 | | of transaction unless the container of the blood is labeled as | 9 | | required by Section 7-110 and, if the container is designated | 10 | | under item (2) of Section 7-110, an acknowledgment from the | 11 | | person receiving the transfusion, or the authorized | 12 | | representative of the person, that the person or | 13 | | representative has been given the opportunity to refuse blood | 14 | | designated under item (2) of Section 7-110 . | 15 | | When blood is administered by transfusion in this State, | 16 | | the identification number of the unit of blood shall be | 17 | | recorded in the patient's medical record and the label on the | 18 | | container of the blood shall not be removed before or during | 19 | | the administration of that blood by transfusion. | 20 | | (Source: P.A. 87-1269.) | 21 | | (210 ILCS 25/7-120 new) | 22 | | Sec. 7-120. Messenger ribonucleic acid (mRNA) vaccine | 23 | | testing and labeling; rules. The Department must adopt rules | 24 | | to implement the changes made by this amendatory Act of the |
| | | HB4243 | - 4 - | LRB103 34691 AWJ 64536 b |
|
| 1 | | 103rd General Assembly. |
|